MannKind: New Approvals Majorly Increase MannKind's Prospects

Out of Ignorance 7.78K Followers Follow Summary Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity should be adequate to fund its operations and launches for ~2.3 years. While I rate MNKD a " Strong Buy" based upon its FDA approvals, it still has significant risks of execution. boygovideo/iStock via Getty Images This is my first article on MannKind ( MNKD ), a developing commercial stage biotech with an ~$1.3 billion market cap. MannKind is enjoying a catalyst-rich 2026, as discussed below. Two new FDA approvals put it at an inflection point This article was written by Out of Ignorance 7.78K Followers Follow Writing under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ~5 years of focused research on a variety of stocks, in recent years with a primary emphasis on healthcare stocks. I greatly appreciate those who take the time to share their reactions to articles, particularly those who share relevant anecdotes and experiences. Analyst’s Disclosure: I/we have a beneficial long position in the shares of UTHR, MNKD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I may buy interests in UTHR and/or MNKD over the next 72 hours. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.